> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tango Therapeutics Encouraging Cancer Drug Data
- URL: https://www.fdaweb.com/tango-therapeutics-encouraging-cancer-drug-data/
- Published: 2025-10-23T12:00:00.000Z
- Updated: 2026-09-14T15:24:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160093

Tango Therapeutics says new data from its ongoing Phase 1-2 study of vopimetostat (TNG462) showed early signs of efficacy across multiple methylthioadenosine phosphorylase (MTAP)-deleted cancers, including pancreatic and lung tumors, paving the way for a pivotal trial next year. Such cancers are described as malignancies characterized by the loss of the MTAP gene, a common genomic alteration that creates a specific metabolic vulnerability in cancer cells, which can be exploited for targeted therapy.

The investigational oral PRMT5 inhibitor achieved a 25% objective response rate and a median progression-free survival (mPFS) of 7.2 months in second-line pancreatic cancer patients — more than double that seen in historical control studies, according to the company. Across 16 cancer types, the ORR was 27%, with a disease control rate of 78% and mPFS of 6.4 months.

Following discussions with FDA later this quarter, Tango plans to launch a global, randomized pivotal trial in 2026 enrolling roughly 300 patients with MTAP-deleted pancreatic cancer who have received one prior line of therapy. Patients will be randomized to receive either vopimetostat 250 mg once daily — the FDA-aligned “go-forward” dose — or one of four standard chemotherapy regimens.

Tango notes that vopimetostat is also being evaluated in combination with two Revolution Medicines RAS(ON) inhibitors — daraxonrasib and zoldonrasib — in patients with MTAP-deleted, RAS-mutant pancreatic and lung cancers. The first dose-escalation cohort has been fully enrolled, with early safety data showing the combination to be well-tolerated, it says.

Additionally, the company says the drug has so far demonstrated a manageable safety and tolerability profile at 250 mg once daily, with most treatment-related adverse events being mild (Grade 1). The most common were nausea (26%), anemia (20%), fatigue (19%), dysgeusia (19%), and thrombocytopenia (13%).